Clinical Trials
11 trialsNCT00052884 2023-06-18
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Eastern Cooperative Oncology Group
Phase 1 Terminated
NCT00303719 2020-05-12
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01875237 2019-07-16
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00005987 2017-11-29
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00290628 2017-11-29
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Masonic Cancer Center, University of Minnesota
Phase NA Terminated
NCT00281879 2017-09-27
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01118013 2017-03-24
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00075608 2017-01-27
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
Boston Medical Center
Phase 2 Terminated
NCT01518153 2016-03-17
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00005852 2012-12-11
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00253552 2012-05-28
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
OHSU Knight Cancer Institute
Phase NA Terminated